The pathogen Clostridioides difficile (C. difficile) is naturally present in the intestines of many people. When present in ...
A retrospective Chinese cohort study finds that serial changes in PCR cycle threshold values for the tcdB gene correlate with ...
Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, ...
A new review in Gut Pathogens argues that SARS-CoV-2 infection and COVID-19 care pathways may create gut conditions ...
In a new study, researchers modeled the transmission of Clostridioides difficile (C. diff) infections among patients in hospital cancer units. They ...
An 86-year-old woman presented to the emergency department with 12 days of persistent nausea, poor oral intake, and weight ...
A wide variety of bacteria live in the human intestine, and the collective group known as the "gut microbiota" is deeply ...
The bacterium can produce spores, tough, dormant forms of some bacteria that can survive outside the body and resist ...
The 2026 Surviving Sepsis Campaign International Guidelines for Management of Sepsis and Septic Shock represent the first major update since 2021 and incorporate new evidence across sepsis recognition ...
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported ...
The researchers are now investigating ways to target the spores and address this new type of antibiotic resistance.
Women with uncomplicated urinary tract infections (uUTIs) saw symptom relief as early as 24 hours after taking gepotidacin, according to the results of a single-arm, nonrandomized clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results